What is Cumberland Pharmaceuticals Return-on-Tangible-Equity?
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Cumberland Pharmaceuticals's annualized net income for the quarter that ended in Dec. 2023 was $-25.18 Mil. Cumberland Pharmaceuticals's average shareholder tangible equity for the quarter that ended in Dec. 2023 was $7.02 Mil. Therefore, Cumberland Pharmaceuticals's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2023 was -358.68%.
The historical rank and industry rank for Cumberland Pharmaceuticals's Return-on-Tangible-Equity or its related term are showing as below:
CPIX'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -115.83 Med: -17.64 Max: 3.94
Current: -95.63
During the past 13 years, Cumberland Pharmaceuticals's highest Return-on-Tangible-Equity was 3.94%. The lowest was -115.83%. And the median was -17.64%.
CPIX's Return-on-Tangible-Equity is ranked worse than 88.89% of 945
companies
in the Drug Manufacturers industry
Industry Median: 6.72
vs CPIX: -95.63
Cumberland Pharmaceuticals Return-on-Tangible-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Cumberland Pharmaceuticals's Return-on-Tangible-Equity
For the Drug Manufacturers - Specialty & Generic subindustry, Cumberland Pharmaceuticals's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cumberland Pharmaceuticals's Return-on-Tangible-Equity Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cumberland Pharmaceuticals's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Cumberland Pharmaceuticals's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Dec. 2023) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Cumberland Pharmaceuticals Return-on-Tangible-Equity Related Terms
Thank you for viewing the detailed overview of Cumberland Pharmaceuticals's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.
Cumberland Pharmaceuticals (Cumberland Pharmaceuticals) Business Description
Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The company's primary target markets are hospital acute care, gastroenterology, rheumatology, and oncology. The company promotes its approved products through its hospital, field, and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. The company's revenue is derived from the product sales of FDA-approved pharmaceutical brands. Its brands include Acetadote, Caldolor, Kristalose, Omeclamox, RediTrex, Sancuso, Vaprisol and Vibativ.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CPIX has been successfully added to your 